Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework.

dc.contributor.author	Ciani, O
dc.contributor.author	Buyse, M
dc.contributor.author	Drummond, M
dc.contributor.author	Rasi, G
dc.contributor.author	Saad, ED
dc.contributor.author	Taylor, RS
dc.date.accessioned	2017-01-09T10:13:11Z
dc.date.issued	2016-06-03
dc.description.abstract	n/a	en_GB
dc.description.sponsorship	O.C. is funded by a postdoctoral research fellowship by the University of Exeter Medical School.	en_GB
dc.identifier.citation	Vol. 15, pp. 516 -	en_GB
dc.identifier.doi	10.1038/nrd.2016.81
dc.identifier.other	nrd.2016.81
dc.identifier.uri	http://hdl.handle.net/10871/25094
dc.language.iso	en	en_GB
dc.publisher	Nature Publishing Group	en_GB
dc.relation.url	https://www.ncbi.nlm.nih.gov/pubmed/27256477	en_GB
dc.subject	Drug regulation	en_GB
dc.subject	Drug development	en_GB
dc.subject	Biomarkers	en_GB
dc.title	Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework.	en_GB
dc.type	Article	en_GB
dc.date.available	2017-01-09T10:13:11Z
dc.identifier.issn	1474-1776
exeter.place-of-publication	England	en_GB
dc.description	Published	en_GB
dc.description	Journal Article	en_GB
dc.description	This is the author accepted manuscript. The final version is available from Nature Publishing Group via the DOI in this record.	en_GB
dc.identifier.eissn	1474-1784
dc.identifier.journal	Nature Reviews Drug Discovery	en_GB